Literature DB >> 1697165

Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat.

Y Vanneste1, S Pauwels, L Lambotte, A Michel, R Dimaline, M Deschodt-Lanckman.   

Abstract

The metabolism of atrial natriuretic peptide (ANP) and Cys-105-Phe-106-cleaved ANP (ANP) was studied during constant infusion of 125I-labelled peptides in rats. Analysis of circulating radioactivity indicated rapid clearance of ANP and ANP', with mean half-lives of 0.42 and 1.04 min respectively. H.p.l.c. fractionation of plasma taken during the infusion of labelled ANP revealed the presence of three radioactive fragments, the major one co-eluting with 125I-ANP'. These fragments correspond to cleavage products previously found to be generated in vitro by the action of endopeptidase 24.11 (E-24.11). On evaluating the effects of peptidase inhibitors, a significant increase in the half-life of ANP was observed with phosphoramidon (t1/2 7.8 min) and aprotinin (t1/2 5.4 min). A maximal inhibition of ANP degradation was obtained when both inhibitors were given simultaneously (t1/2 15 min). In blood samples taken during infusion of 125I-ANP and phosphoramidon, the intact peptide accounted for more than 90% of total circulating radioactivity, and no cleavage product was present in detectable amounts. Phosphoramidon had no effect on the metabolism of infused ANP'. In contrast, when 125I-ANP' was infused together with aprotinin, the rate of degradation of the infused peptide was reduced by more than 80%. It is proposed that two different peptidase activities, E-24.11 and a kallikrein-like proteinase, are responsible for the cleavage of ANP in the circulation. The Cys-Phe-cleaved ANP would in turn be degraded by kallikrein and not by E-24.11.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697165      PMCID: PMC1131658          DOI: 10.1042/bj2690801

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  23 in total

1.  UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic.

Authors:  J C Danilewicz; P L Barclay; I T Barnish; D Brown; S F Campbell; K James; G M Samuels; N K Terrett; M J Wythes
Journal:  Biochem Biophys Res Commun       Date:  1989-10-16       Impact factor: 3.575

Review 2.  Kallikreins (kininogenases)--a group of serine proteases with bioregulatory actions.

Authors:  M Schachter
Journal:  Pharmacol Rev       Date:  1979-03       Impact factor: 25.468

3.  Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney.

Authors:  J L Sonnenberg; Y Sakane; A Y Jeng; J A Koehn; J A Ansell; L P Wennogle; R D Ghai
Journal:  Peptides       Date:  1988 Jan-Feb       Impact factor: 3.750

Review 4.  Structure and function of atrial natriuretic peptides.

Authors:  U Ackermann
Journal:  Clin Chem       Date:  1986-02       Impact factor: 8.327

Review 5.  Kinin formation: mechanisms and role in inflammatory disorders.

Authors:  D Proud; A P Kaplan
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

6.  SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.

Authors:  E J Sybertz; P J Chiu; S Vemulapalli; B Pitts; C J Foster; R W Watkins; A Barnett; M F Haslanger
Journal:  J Pharmacol Exp Ther       Date:  1989-08       Impact factor: 4.030

7.  Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein.

Authors:  H Nolly; A G Scicli; G Scicli; O A Carretero
Journal:  Circ Res       Date:  1985-06       Impact factor: 17.367

8.  In vitro and in vivo degradation of human gastrin by endopeptidase 24.11.

Authors:  M Deschodt-Lanckman; S Pauwels; T Najdovski; R Dimaline; G J Dockray
Journal:  Gastroenterology       Date:  1988-03       Impact factor: 22.682

9.  Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.

Authors:  C Gros; A Souque; J C Schwartz; J Duchier; A Cournot; P Baumer; J M Lecomte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

10.  Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site.

Authors:  Y Vanneste; A Michel; R Dimaline; T Najdovski; M Deschodt-Lanckman
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

View more
  3 in total

1.  Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response.

Authors:  Luis A Ralat; Qing Guo; Min Ren; Todd Funke; Deborah M Dickey; Lincoln R Potter; Wei-Jen Tang
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

2.  In vivo measurement of ANP overall turnover and identification of its main metabolic pathways under steady state conditions in humans.

Authors:  A Clerico; G Iervasi; S Berti; A Pilo; F Vitek; S Salvadori; M Marastoni; C Manfredi; M G Del Chicca; M R Iascone
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

3.  A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation.

Authors:  Deborah M Dickey; Andrea R Yoder; Lincoln R Potter
Journal:  J Biol Chem       Date:  2009-05-19       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.